|
US6599692B1
(en)
|
1999-09-14 |
2003-07-29 |
Sangamo Bioscience, Inc. |
Functional genomics using zinc finger proteins
|
|
US20030104526A1
(en)
|
1999-03-24 |
2003-06-05 |
Qiang Liu |
Position dependent recognition of GNN nucleotide triplets by zinc fingers
|
|
US7465583B2
(en)
|
2000-06-01 |
2008-12-16 |
The University Of North Carolina At Chapel Hill |
Duplexed parvovirus vectors
|
|
US20050144655A1
(en)
|
2000-10-31 |
2005-06-30 |
Economides Aris N. |
Methods of modifying eukaryotic cells
|
|
WO2002046412A2
(en)
|
2000-12-07 |
2002-06-13 |
Sangamo Biosciences, Inc. |
Regulation of angiogenesis with zinc finger proteins
|
|
US7273923B2
(en)
|
2001-01-22 |
2007-09-25 |
Sangamo Biosciences, Inc. |
Zinc finger proteins for DNA binding and gene regulation in plants
|
|
US7947469B2
(en)
|
2001-01-22 |
2011-05-24 |
Gendaq, Ltd. |
Modulation of HIV infection
|
|
US20030108524A1
(en)
|
2001-10-18 |
2003-06-12 |
Melissa Diagana |
Vectors for expressing multiple transgenes
|
|
EP1308517A1
(en)
|
2001-10-31 |
2003-05-07 |
Aventis Pharmacueticals Products Inc. |
Vectors for expressing multiple transgenes
|
|
ATE347593T1
(de)
|
2002-01-23 |
2006-12-15 |
Univ Utah Res Found |
Zielgerichtete chromosomale mutagenese mit zinkfingernukleasen
|
|
EP1504092B2
(en)
|
2002-03-21 |
2014-06-25 |
Sangamo BioSciences, Inc. |
Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
|
|
US9447434B2
(en)
|
2002-09-05 |
2016-09-20 |
California Institute Of Technology |
Use of chimeric nucleases to stimulate gene targeting
|
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
US8409861B2
(en)
|
2003-08-08 |
2013-04-02 |
Sangamo Biosciences, Inc. |
Targeted deletion of cellular DNA sequences
|
|
US7972854B2
(en)
|
2004-02-05 |
2011-07-05 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
KR20070060115A
(ko)
|
2004-09-16 |
2007-06-12 |
상가모 바이오사이언스 인코포레이티드 |
단백질 생산을 위한 조성물 및 방법
|
|
US7951925B2
(en)
|
2006-05-25 |
2011-05-31 |
Sangamo Biosciences, Inc. |
Methods and compositions for gene inactivation
|
|
EP2027262B1
(en)
|
2006-05-25 |
2010-03-31 |
Sangamo Biosciences Inc. |
Variant foki cleavage half-domains
|
|
CA2669746C
(en)
|
2006-12-14 |
2017-05-16 |
Dow Agrosciences Llc |
Optimized non-canonical zinc finger proteins
|
|
US8110379B2
(en)
|
2007-04-26 |
2012-02-07 |
Sangamo Biosciences, Inc. |
Targeted integration into the PPP1R12C locus
|
|
KR20100120226A
(ko)
|
2008-04-11 |
2010-11-12 |
유티씨 파워 코포레이션 |
매니폴드 섬프를 갖는 바이폴라 플레이트 및 연료 전지
|
|
EP3156494B8
(en)
|
2008-12-04 |
2018-09-19 |
Sangamo Therapeutics, Inc. |
Genome editing in rats using zinc-finger nucleases
|
|
US20110239315A1
(en)
|
2009-01-12 |
2011-09-29 |
Ulla Bonas |
Modular dna-binding domains and methods of use
|
|
EP2206723A1
(en)
|
2009-01-12 |
2010-07-14 |
Bonas, Ulla |
Modular DNA-binding domains
|
|
CA2755192C
(en)
|
2009-03-20 |
2018-09-11 |
Sangamo Biosciences, Inc. |
Modification of cxcr4 using engineered zinc finger proteins
|
|
US8772008B2
(en)
|
2009-05-18 |
2014-07-08 |
Sangamo Biosciences, Inc. |
Methods and compositions for increasing nuclease activity
|
|
KR20120097483A
(ko)
|
2009-07-24 |
2012-09-04 |
시그마-알드리치 컴퍼니., 엘엘씨 |
게놈 편집을 위한 방법
|
|
US20120178647A1
(en)
|
2009-08-03 |
2012-07-12 |
The General Hospital Corporation |
Engineering of zinc finger arrays by context-dependent assembly
|
|
WO2011020014A1
(en)
|
2009-08-14 |
2011-02-17 |
Regeneron Pharmaceuticals, Inc. |
Promoter-regulated differentiation-dependent self-deleting cassette
|
|
CN102666854B
(zh)
|
2009-10-29 |
2016-08-24 |
瑞泽恩制药公司 |
多功能等位基因
|
|
PT2816112T
(pt)
|
2009-12-10 |
2018-11-20 |
Univ Iowa State Res Found Inc |
Modificação do adn modificada pelo efector tal
|
|
US9255259B2
(en)
|
2010-02-09 |
2016-02-09 |
Sangamo Biosciences, Inc. |
Targeted genomic modification with partially single-stranded donor molecules
|
|
US9567573B2
(en)
|
2010-04-26 |
2017-02-14 |
Sangamo Biosciences, Inc. |
Genome editing of a Rosa locus using nucleases
|
|
AU2011256838B2
(en)
|
2010-05-17 |
2014-10-09 |
Sangamo Therapeutics, Inc. |
Novel DNA-binding proteins and uses thereof
|
|
DK3693025T3
(da)
|
2011-04-22 |
2022-01-10 |
Univ California |
Adenoassocierede virus-virioner med variant capsid og fremgangsmåder til anvendelse heraf
|
|
EP2758529B1
(en)
|
2011-09-21 |
2019-03-20 |
Sangamo Therapeutics, Inc. |
Methods and compositions for regulation of transgene expression
|
|
US9222105B2
(en)
|
2011-10-27 |
2015-12-29 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of the HPRT locus
|
|
WO2013141680A1
(en)
|
2012-03-20 |
2013-09-26 |
Vilnius University |
RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
|
|
US9637739B2
(en)
|
2012-03-20 |
2017-05-02 |
Vilnius University |
RNA-directed DNA cleavage by the Cas9-crRNA complex
|
|
DK2839013T3
(da)
|
2012-04-18 |
2020-09-14 |
Univ Leland Stanford Junior |
Ikke-disruptiv-gen-targetering
|
|
ES2728782T3
(es)
|
2012-05-25 |
2019-10-28 |
Univ California |
Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
|
|
HUE051612T2
(hu)
|
2012-07-11 |
2021-03-01 |
Sangamo Therapeutics Inc |
Eljárások és készítmények lizoszomális tárolási betegségek kezelésére
|
|
WO2014033644A2
(en)
|
2012-08-28 |
2014-03-06 |
Novartis Ag |
Methods of nuclease-based genetic engineering
|
|
EP4397759A3
(en)
|
2012-10-23 |
2024-10-09 |
Toolgen Incorporated |
Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
|
|
CA2892448A1
(en)
|
2012-12-05 |
2014-06-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of metabolic disorders
|
|
DK3363902T3
(da)
|
2012-12-06 |
2020-01-02 |
Sigma Aldrich Co Llc |
Crispr-baseret genommodifikation og -regulering
|
|
SG10201707569YA
(en)
|
2012-12-12 |
2017-10-30 |
Broad Inst Inc |
Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
CN105209621B
(zh)
|
2012-12-12 |
2021-05-25 |
布罗德研究所有限公司 |
对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
|
|
IL308158A
(en)
|
2012-12-17 |
2023-12-01 |
Harvard College |
Rna-guided human genome engineering
|
|
US10350306B2
(en)
*
|
2013-02-15 |
2019-07-16 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Methods and compositions for treating genetically linked diseases of the eye
|
|
AU2014216160B2
(en)
*
|
2013-02-15 |
2017-03-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
AAV8 retinoschisin expression vector for treating X-linked retinoschisis
|
|
MX2015010841A
(es)
|
2013-02-20 |
2016-05-09 |
Regeneron Pharma |
Modificacion genetica de ratas.
|
|
WO2014131833A1
(en)
|
2013-02-27 |
2014-09-04 |
Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) |
Gene editing in the oocyte by cas9 nucleases
|
|
CN105408483A
(zh)
|
2013-03-15 |
2016-03-16 |
通用医疗公司 |
遗传和表观遗传调节蛋白至特定基因组基因座的rna引导的靶向
|
|
EP4286517A3
(en)
|
2013-04-04 |
2024-03-13 |
President and Fellows of Harvard College |
Therapeutic uses of genome editing with crispr/cas systems
|
|
EP2997146A4
(en)
|
2013-05-15 |
2017-04-26 |
Sangamo BioSciences, Inc. |
Methods and compositions for treatment of a genetic condition
|
|
WO2014204725A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
|
|
JP6738728B2
(ja)
|
2013-06-17 |
2020-08-19 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
肝臓ターゲティングおよび治療のためのＣＲＩＳＰＲ−Ｃａｓ系、ベクターおよび組成物の送達および使用
|
|
SG11201510327TA
(en)
|
2013-06-17 |
2016-01-28 |
Broad Inst Inc |
Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
|
|
WO2015048577A2
(en)
|
2013-09-27 |
2015-04-02 |
Editas Medicine, Inc. |
Crispr-related methods and compositions
|
|
DE102013111099B4
(de)
|
2013-10-08 |
2023-11-30 |
Eberhard Karls Universität Tübingen Medizinische Fakultät |
Permanente Genkorrektur mittels nukleotidmodifizierter messenger RNA
|
|
CA3229275A1
(en)
|
2013-12-09 |
2015-06-18 |
Sangamo Biosciences, Inc. |
Methods and compositions for genome engineering
|
|
WO2015089419A2
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
|
|
CN111206032B
(zh)
|
2013-12-12 |
2024-07-19 |
布罗德研究所有限公司 |
用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用
|
|
EP3110454B1
(en)
|
2014-02-24 |
2020-11-18 |
Sangamo Therapeutics, Inc. |
Methods and compositions for nuclease-mediated targeted integration
|
|
US10612041B2
(en)
|
2014-03-21 |
2020-04-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Genome editing without nucleases
|
|
WO2015191693A2
(en)
|
2014-06-10 |
2015-12-17 |
Massachusetts Institute Of Technology |
Method for gene editing
|
|
AU2015277369B2
(en)
|
2014-06-16 |
2021-08-19 |
The Johns Hopkins University |
Compositions and methods for the expression of CRISPR guide RNAs using the H1 promoter
|
|
WO2015200555A2
(en)
|
2014-06-25 |
2015-12-30 |
Caribou Biosciences, Inc. |
Rna modification to engineer cas9 activity
|
|
CN106794141B
(zh)
|
2014-07-16 |
2021-05-28 |
诺华股份有限公司 |
将核酸包封在脂质纳米粒主体中的方法
|
|
CA2969619A1
(en)
|
2014-12-03 |
2016-06-09 |
Agilent Technologies, Inc. |
Guide rna with chemical modifications
|
|
CN113337533A
(zh)
|
2014-12-23 |
2021-09-03 |
先正达参股股份有限公司 |
用于鉴定和富集包含位点特异性基因组修饰的细胞的方法和组合物
|
|
WO2016106236A1
(en)
|
2014-12-23 |
2016-06-30 |
The Broad Institute Inc. |
Rna-targeting system
|
|
CN107787367B
(zh)
|
2015-04-06 |
2021-10-26 |
里兰斯坦福初级大学理事会 |
用于crispr/cas介导的基因调控的化学修饰的引导rna
|
|
EP3289080B1
(en)
|
2015-04-30 |
2021-08-25 |
The Trustees of Columbia University in the City of New York |
Gene therapy for autosomal dominant diseases
|
|
US20160346359A1
(en)
|
2015-05-01 |
2016-12-01 |
Spark Therapeutics, Inc. |
Adeno-associated Virus-Mediated CRISPR-Cas9 Treatment of Ocular Disease
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
US11279928B2
(en)
|
2015-06-29 |
2022-03-22 |
Massachusetts Institute Of Technology |
Compositions comprising nucleic acids and methods of using the same
|
|
EP3159407A1
(en)
|
2015-10-23 |
2017-04-26 |
Silence Therapeutics (London) Ltd |
Guide rnas, methods and uses
|
|
US11866727B2
(en)
|
2015-11-06 |
2024-01-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of glycogen storage disease type 1A
|
|
CN106893739A
(zh)
|
2015-11-17 |
2017-06-27 |
香港中文大学 |
用于靶向基因操作的新方法和系统
|
|
EP3380622A4
(en)
|
2015-11-23 |
2019-08-07 |
Sangamo Therapeutics, Inc. |
METHODS AND COMPOSITIONS FOR MODIFYING IMMUNITY
|
|
WO2017093804A2
(en)
|
2015-12-01 |
2017-06-08 |
Crispr Therapeutics Ag |
Materials and methods for treatment of alpha-1 antitrypsin deficiency
|
|
CA3009308A1
(en)
|
2015-12-23 |
2017-06-29 |
Chad Albert COWAN |
Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
|
|
EP3411078A1
(en)
|
2016-02-02 |
2018-12-12 |
Crispr Therapeutics AG |
Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
|
|
WO2017136794A1
(en)
|
2016-02-03 |
2017-08-10 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
|
WO2017141109A1
(en)
|
2016-02-18 |
2017-08-24 |
Crispr Therapeutics Ag |
Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
|
|
US11083799B2
(en)
|
2016-03-16 |
2021-08-10 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hereditary haemochromatosis
|
|
ES3030658T3
(en)
|
2016-03-30 |
2025-07-01 |
Intellia Therapeutics Inc |
Lipid nanoparticle formulations for crispr/cas components
|
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
|
US11427838B2
(en)
|
2016-06-29 |
2022-08-30 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
|
|
WO2018007871A1
(en)
|
2016-07-08 |
2018-01-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of transthyretin amyloidosis
|
|
US11603533B2
(en)
|
2016-07-12 |
2023-03-14 |
Washington University |
Incorporation of internal polya-encoded poly-lysine sequence tags and their variations for the tunable control of protein synthesis in bacterial and eukaryotic cells
|
|
CA3030587A1
(en)
|
2016-07-15 |
2018-01-18 |
Salk Institute For Biological Studies |
Methods and compositions for genome editing in non-dividing cells
|
|
WO2020046861A1
(en)
|
2018-08-27 |
2020-03-05 |
Avellino Lab Usa, Inc. |
Crispr/cas9 systems, and methods of use thereof
|
|
JP7256739B2
(ja)
|
2016-09-07 |
2023-04-12 |
サンガモ セラピューティクス， インコーポレイテッド |
肝臓遺伝子のモジュレーション
|
|
CA3034931A1
(en)
|
2016-09-23 |
2018-03-29 |
Board Of Trustees Of Southern Illinois University |
Tuning crispr/cas9 activity with chemically modified nucleotide substitutions
|
|
EP3551757A1
(en)
|
2016-12-08 |
2019-10-16 |
Intellia Therapeutics, Inc. |
Modified guide rnas
|
|
US20180185516A1
(en)
|
2016-12-09 |
2018-07-05 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
|
RU2019121801A
(ru)
|
2016-12-14 |
2021-01-15 |
Лигандал, Инк. |
Композиции и способы для доставки полезной нагрузки в виде нуклеиновой кислоты и/или белка
|
|
US11597947B2
(en)
|
2016-12-29 |
2023-03-07 |
Asc Therapeutics Inc. |
Gene editing method using virus
|
|
EP3585899A1
(en)
|
2017-02-22 |
2020-01-01 |
CRISPR Therapeutics AG |
Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders
|
|
EP3635121A1
(en)
|
2017-06-02 |
2020-04-15 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Viral vector combining gene therapy and genome editing approaches for gene therapy of genetic disorders
|
|
US11667934B2
(en)
|
2017-06-15 |
2023-06-06 |
Toolgen Incorporated |
Platform for expressing protein of interest in liver
|
|
CN111032867A
(zh)
|
2017-06-16 |
2020-04-17 |
应用干细胞有限公司 |
具有提高的敲入效率的基因编辑方法
|
|
WO2019010384A1
(en)
|
2017-07-07 |
2019-01-10 |
The Broad Institute, Inc. |
METHODS FOR DESIGNING GUIDE SEQUENCES FOR GUIDED NUCLEASES
|
|
CN111094573A
(zh)
|
2017-07-12 |
2020-05-01 |
梅约医学教育与研究基金会 |
有效靶向敲入或基因置换的材料和方法
|
|
JP7335224B2
(ja)
|
2017-07-18 |
2023-08-29 |
ジェノヴィー エービー |
全長ｔ細胞受容体オープンリーディングフレームの迅速な組立ておよび多様化のための二成分ベクターライブラリシステム
|
|
KR102712142B1
(ko)
|
2017-07-31 |
2024-10-07 |
리제너론 파마슈티칼스 인코포레이티드 |
Cas-형질전환 마우스 배아 줄기 세포 및 마우스 및 이것의 용도
|
|
JP2020532961A
(ja)
|
2017-08-15 |
2020-11-19 |
インテリア セラピューティクス，インコーポレイテッド |
メッセンジャーリボ核酸（ｍＲＮＡ）をコードする安定化された核酸
|
|
IL311278B2
(en)
|
2017-09-29 |
2026-05-01 |
Intellia Therapeutics Inc |
Polynucleotides, compositions, and methods for genome editing
|
|
EP3688162B1
(en)
|
2017-09-29 |
2024-03-06 |
Intellia Therapeutics, Inc. |
Formulations
|
|
US20220080055A9
(en)
|
2017-10-17 |
2022-03-17 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing for hemophilia a
|
|
EP3704245A1
(en)
|
2017-11-01 |
2020-09-09 |
Novartis AG |
Synthetic rnas and methods of use
|
|
EP3714055A1
(en)
|
2017-11-21 |
2020-09-30 |
CRISPR Therapeutics AG |
Materials and methods for treatment of autosomal dominant retinitis pigmentosa
|
|
JP2021505159A
(ja)
|
2017-12-06 |
2021-02-18 |
ジェネレーション バイオ カンパニー |
修飾型閉端ｄｎａ（ｃｅｄｎａ）を使用する遺伝子編集
|
|
WO2019118875A1
(en)
|
2017-12-15 |
2019-06-20 |
Ou Li |
Crispr-mediated genome editing with vectors
|
|
US11891635B2
(en)
|
2017-12-21 |
2024-02-06 |
Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft |
Nucleic acid sequence replacement by NHEJ
|
|
WO2019134561A1
(en)
|
2018-01-05 |
2019-07-11 |
The Chinese University Of Hong Kong |
High efficiency in vivo knock-in using crispr
|
|
EP3737762A1
(en)
|
2018-01-12 |
2020-11-18 |
CRISPR Therapeutics AG |
Compositions and methods for gene editing by targeting transferrin
|
|
EP3752616A1
(en)
|
2018-02-16 |
2020-12-23 |
CRISPR Therapeutics AG |
Compositions and methods for gene editing by targeting fibrinogen-alpha
|
|
EP3768327A4
(en)
|
2018-03-23 |
2022-04-13 |
The Trustees of Columbia University in the City of New York |
GENE EDIT FOR AUTOSOMAL DOMINANT DISEASES
|
|
EP3787694A4
(en)
|
2018-04-29 |
2022-05-18 |
University of Massachusetts |
RAAV-MEDIATED NUCLEASE-ASSOCIATED VECTOR INTEGRATION (RAAV-NAVI)
|
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
|
JP7832761B2
(ja)
|
2018-06-08 |
2026-03-18 |
インテリア セラピューティクス，インコーポレイテッド |
遺伝子編集のための修飾されたガイドｒｎａ
|
|
WO2019239361A1
(en)
|
2018-06-14 |
2019-12-19 |
Novartis Ag |
Method for sequence insertion using crispr
|
|
GB2596224B
(en)
|
2018-06-19 |
2022-09-07 |
Univ Texas |
Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
|
|
US12275935B2
(en)
|
2018-06-27 |
2025-04-15 |
Altius Institute For Biomedical Sciences |
Gapped and tunable repeat units for use in genome editing and gene regulation compositions
|
|
WO2020006131A2
(en)
|
2018-06-27 |
2020-01-02 |
Altius Institute For Biomedical Sciences |
Nucleases for genome editing
|
|
WO2020006126A1
(en)
|
2018-06-27 |
2020-01-02 |
Altius Institute For Biomedical Sciences |
Nucleic acid binding domains and methods of use thereof
|
|
EP3814499A2
(en)
|
2018-06-28 |
2021-05-05 |
CRISPR Therapeutics AG |
Compositions and methods for genomic editing by insertion of donor polynucleotides
|
|
EP3820503A4
(en)
|
2018-07-13 |
2022-07-13 |
Allele Biotechnology & Pharmaceuticals, Inc. |
METHODS FOR HIGH SPECIFICITY GENOME EDITING
|
|
WO2020032986A1
(en)
|
2018-08-10 |
2020-02-13 |
Logicbio Therapeutics, Inc. |
Non-disruptive gene therapy for the treatment of mma
|
|
WO2020047531A1
(en)
|
2018-08-31 |
2020-03-05 |
The Children's Hospital Of Philadelphia |
Scalable tagging of endogenous genes by homology-independent intron targeting
|
|
WO2020055941A1
(en)
|
2018-09-13 |
2020-03-19 |
Excision Biotherapeutics, Inc. |
Compositions and methods for excision with single grna
|
|
MX2021003455A
(es)
|
2018-10-02 |
2021-09-21 |
Intellia Therapeutics Inc |
Lípidos con amina ionizables.
|
|
US12285495B2
(en)
|
2018-10-15 |
2025-04-29 |
Fondazione Telethon Ets |
Genome editing methods and constructs
|
|
IL326835A
(en)
|
2018-10-16 |
2026-04-01 |
Blueallele Llc |
Methods for targeted insertion of dna genes
|
|
CA3116138A1
(en)
|
2018-10-17 |
2020-04-23 |
Senti Biosciences, Inc. |
Combinatorial cancer immunotherapy
|
|
JP7520826B2
(ja)
|
2018-10-17 |
2024-07-23 |
クリスパー・セラピューティクス・アクチェンゲゼルシャフト |
導入遺伝子を送達するための組成物および方法
|
|
JP7578590B2
(ja)
|
2018-10-18 |
2024-11-06 |
インテリア セラピューティクス，インコーポレーテッド |
第ｉｘ因子を発現するための組成物及び方法
|
|
MX2021004276A
(es)
|
2018-10-18 |
2021-09-08 |
Intellia Therapeutics Inc |
Composiciones y metodos para tratar deficiencia de alfa-1 antitripsina.
|
|
BR112021007343A2
(pt)
|
2018-10-18 |
2021-08-03 |
Intellia Therapeutics, Inc. |
composições e métodos para expressão de transgene a partir de um lócus de albumina
|
|
CN113272428A
(zh)
|
2018-10-18 |
2021-08-17 |
英特利亚治疗股份有限公司 |
核酸构建体和使用方法
|
|
CA3121191A1
(en)
|
2018-11-28 |
2020-06-04 |
Crispr Therapeutics Ag |
Optimized mrna encoding cas9 for use in lnps
|
|
CN119285480A
(zh)
|
2018-12-05 |
2025-01-10 |
英特利亚治疗股份有限公司 |
改性的胺脂质
|
|
SG11202108357PA
(en)
|
2019-02-15 |
2021-08-30 |
Crispr Therapeutics Ag |
Gene editing for hemophilia a with improved factor viii expression
|
|
US11702644B2
(en)
|
2019-04-11 |
2023-07-18 |
California Institute Of Technology |
Methods and compositions for in vivo gene editing based cell-type-specific cellular engineering
|
|
WO2020219876A1
(en)
|
2019-04-25 |
2020-10-29 |
Intellia Therapeutics, Inc. |
Ionizable amine lipids and lipid nanoparticles
|
|
US12521451B2
(en)
|
2019-11-08 |
2026-01-13 |
Regeneron Pharmaceuticals, Inc. |
CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy
|
|
AU2021246006A1
(en)
|
2020-03-30 |
2022-10-20 |
Blueallele, Llc |
Methods for integrating DNA into genes with gain-of-function or loss-of-function mutations
|
|
JP7891314B2
(ja)
|
2020-05-06 |
2026-07-16 |
セレクティス ソシエテ アノニム |
治療用タンパク質の送達のために細胞を遺伝子改変する方法
|